These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The development comes as stroke remains one of the world’s biggest health threats
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Millions of stroke survivors across the world may soon have a new defense
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
